Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 6, 2006, Pages 535-540

  Saito, M ^a   Nakayama, D ^b   Takada, M ^c   Hirooka, K ^a   Yasumura, Y ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Candesartan cilexetil; Carvedilol; Enalapril maleate; Furosemide; Hyperkalemia; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; FUROSEMIDE; NITROGEN; POTASSIUM; SODIUM; SPIRONOLACTONE; UREA;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CARBAZOLES; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; POTASSIUM; PROPANOLAMINES; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TETRAZOLES;

EID: 33751358958     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00772.x     Document Type: Article

References (15)

1. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICS) Study Group. (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation, 106, 2194-2199.
2. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709-717.
3. Pfeffer MA, Swedberg K, Granger CB et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet, 362, 759-766.
4. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine, 327, 685-691.
5. Ross EJ (1965) Aldosterone and its antagonists. Clinical Pharmacology and Therapeutics, 6, 65-106.
6. Singer MM, DeGraff AC (1964) Diuretic therapy. VII. Spironolactone. American Heart Journal, 68, 835-837.
7. Liddle GW (1966) Aldosterone antagonists and triamterene. Annals of the New York Academy of Sciences, 139, 466-470.
8. Clausen T, Flatman JA (1980) Beta2-adrenoceptors mediate the stimulating effect of the adrenaline on active electrogenic Na-K transport in rat soleus muscle. British Journal of Pharmacology 68, 749-755.
9. Shah KB, Rao K, Sawyer R, Gottlieb SS (2005) The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. Journal of the American College of Cardiology, 46, 845-849.
10. Pitt B, Remme W, Zannad F et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309-1321.
11. The Randomized Aldactone Evaluation Study (RALES) Investigators (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). American Journal of Cardiology, 78, 902-907.
12. Wong PC, Price WA Jr, Chui AT et al. (1990) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP753, an orally active antihypertensive agent. Pharmacology and Experimental Therapeutics, 255, 211-217.
13. See S, Stirling AL (2000) Candesartan cilexetil: an angiotensin II-receptor blocker. American Journal of Health-System Pharmacists, 57, 739-746.
14. Reardon LC, Macpherson DS (1998) Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: How much should we worry? Archives of Internal Medicine, 158, 26-32.
15. Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y (2005) Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Journal of Clinical Pharmacy and Therapeutics, 30, 603-610.